Japan introduced a new health coverage scheme for long-listed products (LLPs) on October 1. A survey of generic drug makers…
HOME > REGULATORY
REGULATORY
- CSIMC’s DPC Subcommittee to Reconsider Use of Functional Evaluation Coefficient II to Evaluate Rate of Generic Drug Use
August 30, 2013
- MHLW’s Health Bureau to Seek 408.9 Billion Yen for 2014 Budget, 21.1 Billion for Infectious Disease Prevention
August 29, 2013
- HPB’s FY2014 Budget Request Earmarks Funds to Strength System of Hospitals that Accept All Emergency Patients
August 29, 2013
- University Hospitals Asked to Inspect Own Clinical Trials amid Diovan Jitters
August 28, 2013
- MHLW Budget Requests Feature 114.1 Billion Yen for Japan NIH, Drug Discovery Network
August 28, 2013
- MHLW’s Economic Affairs Division Honing in on “4th Round” of Distribution Reform; Era of Bundling Won’t Return
August 27, 2013
- Second Committee Recommends Approval for Japan’s First LABA/LAMA Combination Drug
August 27, 2013
- PMDA Provides Risk Information on 10 Ethical Drugs Currently Under Evaluation
August 27, 2013
- New Ethical Guidelines to Include Preventive Measures against Misconduct in Research: Health, Education Ministries’ Interim Report
August 26, 2013
- Council Calls for Sharper Price Reductions for Long-Listed Drugs, Increase in Operating Profit Rate When Using Cost Calculation Method
August 26, 2013
- Applicants Objected to Proposed NHI Prices for 16 APIs in April 2010-May 2013; Revisions Made for 5 APIs
August 26, 2013
- First Committee Recommends Approval of Takeda’s Anti-Obesity Drug OBLEAN, Other Products
August 26, 2013
- Bill Payer and Healthcare Reps Support MHLW Proposal to Reduce NHI Prices; Industry Reps Want a Hold on a Decision
August 26, 2013
- Pharma Industry to Give Opinions at CSIMC Subcommittee in Sept., Stand against Health Ministry’s Plan to Cut Drug Prices
August 26, 2013
- CSIMC Sets No Prescription Limit for Irtra Combination Tablets
August 23, 2013
- CSIMC Approves Listing of 12 APIs, Parjeta Gets 5% Premium for Usefulness
August 23, 2013
- MHLW Proposes Plan to Downwardly Revise NHI Prices of Combination Drugs and Drugs Obtained as a Result of Optical Resolution of Racemic Bodies
August 23, 2013
- “Zero Risk” of Tumorigenicity from Products Using iPS Cells Cannot Be Guaranteed at Present: PMDA’s Science Board
August 23, 2013
- Health Ministry Notifies Prefectures of Approval for Xolair, Other Products
August 22, 2013
- MHLW to Draft New Guidance on Companion Diagnostics by End of 2013: Director Sato of ELD
August 20, 2013
ページ
It’s easy to spot motivated and engaged employees. They are more productive, they go the extra mile, and they display a sense of ownership in their work.But how do you replicate this culture throughout your organization? How do you encourage…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…